Pfizer-backed Priovant wins FDA priority review for lead asset
Priovant Therapeutics, a company backed by Pfizer (PFE) and Roivant Sciences (ROIV), announced on Tuesday that the U.S. FDA has granted priority review for its marketing application targeted at its lead asset, brepocitinib. With its New Drug Application,...
Seeking Alpha